Barclays PLC Acquires 22,769 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Barclays PLC raised its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 10.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 234,069 shares of the company’s stock after purchasing an additional 22,769 shares during the period. Barclays PLC owned 0.11% of Lineage Cell Therapeutics worth $118,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of LCTX. Fort Sheridan Advisors LLC increased its holdings in shares of Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after acquiring an additional 23,000 shares during the period. HighTower Advisors LLC raised its holdings in Lineage Cell Therapeutics by 49.5% in the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after purchasing an additional 19,100 shares during the period. Atria Wealth Solutions Inc. acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter valued at approximately $29,000. SG Americas Securities LLC grew its stake in Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after acquiring an additional 18,053 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Lineage Cell Therapeutics by 33.0% in the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock valued at $48,000 after buying an additional 23,527 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

Analysts Set New Price Targets

LCTX has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. B. Riley cut their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Finally, D. Boral Capital reiterated a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Trading Down 2.6%

Shares of NYSEAMERICAN LCTX opened at $0.46 on Thursday. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.37 and a 12-month high of $1.15. The company has a market cap of $100.95 million, a price-to-earnings ratio of -3.82 and a beta of 1.21. The stock’s 50 day simple moving average is $0.46 and its 200 day simple moving average is $0.63.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.